2015
DOI: 10.1038/npjamd.2015.8
|View full text |Cite
|
Sign up to set email alerts
|

The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer’s disease

Abstract: Age-dependent cognitive decline is a major debilitating event affecting even individuals who are otherwise healthy. Understanding the molecular basis underlying these changes may increase the healthspan of the elderly population. It may also reveal insights into the pathogenesis of numerous neurodegenerative disorders characterized by cognitive deficits, as aging is the major risk factor for most of these disorders. Alzheimer’s disease (AD), the most common neurodegenerative disorder, first manifests itself as… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
47
0
1

Year Published

2016
2016
2021
2021

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 64 publications
(50 citation statements)
references
References 94 publications
(122 reference statements)
2
47
0
1
Order By: Relevance
“…This is considered an acute rapamycin effect rather than a chronic effect. This result agrees with the findings of previous studies showing that acute local administration of rapamycin impairs learning and memory formation [41,43,44,50,5456]. Although rapamycin was previously reported to be capable of crossing the blood-brain barrier [57], the general whole-body effects of rapamycin and the local effect of rapamycin on the brain should be distinguished because the concentration and localization of rapamycin are considered to differ following peroral versus regional administration.…”
Section: Discussionsupporting
confidence: 93%
“…This is considered an acute rapamycin effect rather than a chronic effect. This result agrees with the findings of previous studies showing that acute local administration of rapamycin impairs learning and memory formation [41,43,44,50,5456]. Although rapamycin was previously reported to be capable of crossing the blood-brain barrier [57], the general whole-body effects of rapamycin and the local effect of rapamycin on the brain should be distinguished because the concentration and localization of rapamycin are considered to differ following peroral versus regional administration.…”
Section: Discussionsupporting
confidence: 93%
“…First, locomotor deficits in HSP are believed to be associated with degeneration of specific subsets of neurons within the brain and spinal cord. Although the mechanisms underlying the neurodegeneration that is presumed to occur in HSPs are unknown, neurodegeneration in other disorders, such as Alzheimer's, Parkinson's and Huntington's diseases, appear to involve Tor activation (reviewed recently in Talboom et al, 2015) and appear to be sensitive to rapamycin administration. Our results support the notion that the degeneration in atl-mediated HSP might likewise be caused by Tor activation; if so, the development of this HSP would be placed within the same framework as the mechanisms underlying the other neurodegenerative disorders listed above.…”
Section: Cellular Degeneration and Clinical Features In Hspmentioning
confidence: 99%
“…Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that is activated by Akt. It regulates protein synthesis and degradation, cell survival, proliferation and longevity . Thus, dysregulation of mTOR may contribute to disease pathogenesis .…”
Section: Introductionmentioning
confidence: 99%
“…It regulates protein synthesis and degradation, cell survival, proliferation and longevity . Thus, dysregulation of mTOR may contribute to disease pathogenesis . mTOR also plays a role in nutrient sensing and is activated in the liver and other tissues in individuals with obesity and non‐alcoholic fatty liver disease .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation